The Mitchell viewpoint
13 May, 2002 by Melissa TrudingerDr Graham Mitchell is in a unique position to comment on biotechnology in Victoria. As one of the four scientists in biotech consultancy Foursight Associates, he is one of the chief scientific advisers to the Victorian government.
How to achieve perfect pitch
13 May, 2002 by Daniella GoldbergWith years of experience in the business of science and training as a scientist as well as in business management, Cerylid Biosciences CEO Dr Jackie Fairley is well equipped to give advice on the pitch, whether it's in the elevator or at a venture capital forum.
Biotech 'grossly under-invested': QIC
13 May, 2002 by Melissa TrudingerAustralia's biotechnology sector is "grossly under-invested" and attracts little interest from most funds and investors, according to a senior portfolio manager at Queensland Investment Corporation.
Industry heavyweight calls for better R&D base
13 May, 2002 by Iain ScottEffective R&D policy would include more flexible career opportunities for scientists, according to Vision Systems managing director Dr Jim Fox.
Qld's biotech bid grows by another $100m
10 May, 2002 by Melissa TrudingerThe Queensland government has gone one-up on the State and Federal governments by announcing a new $100 million Queensland BioCapital Fund.
Aeris to market indoor biofilm technology
10 May, 2002 by Iain Scott'Environmental biotechnology' usually conveys a mental image of vats of bacteria busily working on soil remediation. But the issue of indoor air quality is fast becoming an important area of focus in the life sciences arena, according to Sydney-based company Aeris Technologies.
Axon announces loss, shares drop
10 May, 2002 by Tanya HollisShares in Axon Instruments suffered a kick in the guts after a shareholder update revealed unexpected losses of up to $US4 million in the six months to June.
VCs to run new $107m pre-seed plan
10 May, 2002 by Pete YoungLarge venture capital entities have snared all four of the licences to manage the Federal government's new $107 million plan to fill the pre-seed funding gap facing promising technologies.
CSL slide continues despite 'buy' status
10 May, 2002 by Tanya HollisInvestors continued to punish biotech big gun CSL today, despite analysts recommending the stock as a definite buy.
HIPAA compliance: the clock is ticking
09 May, 2002 by Cara GarretsonWith the first deadline to implement new medical record regulations less than a year away, bioscience companies should be taking a hard look at whether these complicated US federal mandates will affect them.
MBAs told to go offshore for biotech experience
08 May, 2002 by Daniella GoldbergBusiness management students were told yesterday that they may have to work overseas before they sought employment in Australia's biotechnology industry.
Research consortium seeks government support
08 May, 2002 by Tanya HollisA consortium of eight research groups is pitching for Victorian Government support in a bid to become Australia's first fee-for-service pharmaceutical pipeline group.
Vic Budget brings in the bucks for biotech
08 May, 2002 by Tanya HollisVictoria's government has unveiled a cash injection of $68.7 million for biotechnology and commercialisation, including a doubling in funding for medical research infrastructure in a bid to lure top scientists back to the state.
Tech CEOs tip biotech growth
07 May, 2002 by Daniella GoldbergCEOs of Australia's leading technology companies believe that the biotechnology and internet security sectors have the greatest potential for growth in the next 12 months, according to a Deloitte industry survey.
Hawke steps down from Autogen board
07 May, 2002 by Tanya HollisFormer Prime Minister Bob Hawke has resigned as a director of Autogen's board, citing heavy business and personal commitments.
